Vol 55, No 3 (2024)
Clinical vignette
Published online: 2024-06-26

open access

Page views 104
Article views/downloads 45
Get Citation

Connect on Social Media

Connect on Social Media

Succesful CPX-351 treatment of seminoma therapy-related acute myeloid leukemia in a patient with Klinefelter syndrome

Natalia Bujko-Wasiak1, Wiesław Wiktor Jędrzejczak1, Agnieszka Brzozowska12, Piotr Petrasz3, Katarzyna Brzeźniakiewicz-Janus12
DOI: 10.5603/ahp.99607
Acta Haematol Pol 2024;55(3):177-179.

Abstract

Therapy-related acute myeloid leukemia (t-AML) is one of the most severe distant complications of cancer treatment. With the prolonged survival of patients cured of neoplasia the issue of distant complications becomes significant. Both, radiation and cytotoxic drugs used in such therapy, are mutagenic and the risk of development of t-AML reaches 1% per year in some studies. Moreover, t-AML is more resistant to treatment than primary leukemia, while patients may be more fragile to adverse effects than subjects not earlier exposed to cytotoxic therapies. Hence, need to use novel and less toxic approaches to their treatment. One of the newly available compounds is CPX-351: liposomal preparation of cytosine arabinoside with daunorubicin. Below we report its successful use in the AML patient with Klinefelter syndrome earlier cured of seminoma.

Article available in PDF format

View PDF Download PDF file

References

  1. Szmajda D, Balcerczak E, Krygier A. Standardy diagnostyki oraz nowe trendy w leczeniu ostrej białaczki szpikowej. Acta Haematol Pol. 2017; 48(4): 291–299.
  2. Lancet JE, et al. A Case Study in Secondary AML: Best practice for treatment selection. Treatment. 2021(January 20).
  3. Molica M, Perrone S, Mazzone C, et al. CPX-351: an old scheme with a new formulation in the treatment of high-risk AML. Cancers (Basel). 2022; 14(12): 2843.
  4. Williams LA, Pankratz N, Lane J, et al. Klinefelter syndrome in males with germ cell tumors: A report from the Children's Oncology Group. Cancer. 2018; 124(19): 3900–3908.
  5. Lancet J, Rizzieri D, Schiller G, et al. Outcomes in patients with therapy-related acute myeloid leukemia (t-AML) who achieved remission with CPX-351 versus 7+3: phase 3 exploratory analysis. Blood. 2019; 134(Supplement_1): 1313.
  6. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018; 36(26): 2684–2692.